Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748055 | 1.00 | CYP2D6 (0.39) | CYP2D6SLC6A2SLC6A4NOS2MAPT | |
| SCHEMBL6842377 | 0.82 | CYP2D6 (0.52) | CYP2D6SLC6A2SLC6A4NOS2MAPT | |
| SCHEMBL6750975 | 0.82 | CYP2D6 (0.52) | CYP2D6SLC6A2SLC6A4NOS2MAPT | |
| SCHEMBL6750065 | 0.81 | CYP2D6 (0.41) | CYP2D6SLC6A2SLC6A4NOS2MAPT | |
| SCHEMBL6752559 | 0.81 | CYP2D6 (0.37) | CYP2D6SLC6A2SLC6A4NOS2MAPT | |
| SCHEMBL6746236 | 0.79 | BRD4 (0.34) | CYP2D6SLC6A2SLC6A4NOS2SPHK1 | |
| SCHEMBL16160941 | 0.79 | EGFR (0.32) | SPHK1 | |
| SCHEMBL6750046 | 0.78 | CYP2D6 (0.37) | CYP2D6SLC6A2SLC6A4NOS2ALDH1A1 | |
| SCHEMBL6750156 | 0.77 | KDM4E (0.37) | SPHK1BRD4HSD11B2 | |
| SCHEMBL6750153 | 0.77 | KDM4E (0.37) | SPHK1BRD4HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | CYP2D6 48/4885SLC6A2 2580/4885SLC6A4 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.